Drug patents
Big pharmaceutical companies in the US are rejoicing over a new Food and Drug Administration ruling that gives them an extension of 3 years on their drug patents. Consumer groups are not exactly delighted at the change because it could cost consumers billions of dollars, since companies that make cheaper "generic" alternatives to brand-name drugs on which the patents have expired would be left out in the cold. These companies have called on the Congress to amend the law.
Related Content
- Order of the High Court of Kerala regarding pricing of breast cancer medicines, 02/11/2023
- Order of the High Court of Delhi regarding supply and availability of the drug Tocilizumab 400 MG for COVID-19 patients, 10/05/2021
- Intellectual property evolution and innovation ecosystem as effective tools in strengthening Indian healthcare sector
- Global hepatitis report, 2017
- Open Source Drug Discovery: Highly potent antimalarial compounds derived from the tres cantos arylpyrroles
- Guidelines for the examination of patent applications relating to pharmaceuticals